ALSO NOTED: Pipex downsizes; Merck chief got 80% pay hike; Biosignal licences tech;and much more...

> Late last year it was fashionable to talk about Merck's dramatic turnaround. So, how much was that vaunted turnaround worth? Try $14.5 million in compensation for CEO Richard T. Clark (photo). Report

> Pipex Pharmaceuticals eliminated 14 positions as part of a cost-savings move. Pipex is facing a likely delay refiling its NDA for oral tetrathiomolybdate for the treatment of initially presenting neurologic Wilson's disease. Release

> Australia's Biosignal has agreed to license its anti-bacterial technology to a U.S. entrepreneur. Report

> Vietnam is stepping up plans to boost its biotech industry so that it can be competitive with other countries in Southeast Asia by 2020. Story

> Should the feds send out their own pharma reps? Wednesday, the Senate Special Committee on Aging will convene to discuss "academic detailing," which is essentially a straight talk express for pharma. Report

> Cognizant Technologies has inked a five-year deal with AstraZeneca on the delivery of clinical data management services. Report

> Drugmakers are having a more difficult time keeping patent protection on their products, the Financial Times notes. Report

> Scientists at the Virginia Bioinformatics Institute used a new computer modeling program supported by the NIH to simulate how a lethal pandemic flu outbreak could hit a modern American city. Report

And Finally... Adult-age offspring of parents who have both been diagnosed with Alzheimer's disease appear to have an increased risk of developing the disease compared with the general population, according to a new report. Release

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.